Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
5
63%
Ph phase_1
1
13%
Ph phase_2
2
25%

Phase Distribution

1

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 3Large-scale testing
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 22 (25.0%)
Phase 35 (62.5%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_3

A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects

NCT03351166
completedphase_3

Maintenance Treatment of Renal Anemia in Dialysis Subjects

NCT03543657
completedphase_3

A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects

NCT03350321
completedphase_3

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects

NCT03350347
completedphase_3

A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects

NCT03418168
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03351166Phase 3

A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects

Completed
NCT03543657Phase 3

Maintenance Treatment of Renal Anemia in Dialysis Subjects

Completed
NCT03350321Phase 3

A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects

Completed
NCT03350347Phase 3

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects

Completed
NCT03418168Phase 3

A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects

Completed
NCT02064426Phase 2

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

Completed
NCT02055482Phase 2

Long-term Pre-dialysis Extension in Europe and Asia Pacific

Completed
NCT01679587Phase 1

Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8